Incuvate has filed a patent-infringement lawsuit against Penumbra in U.S. District Court for the Northern District of California, alleging that Penumbra's THUNDERBOLT Neurovascular Thrombectomy System and related components infringe five Incuvate patents covering real-time aspiration monitoring technology. Incuvate is seeking damages, injunctive relief, and other remedies.

GuideAI Health Corp. announced the appointment of renowned interventional radiologist Dr. James Benenati, Chief Medical Officer of Penumbra Inc., to its Advisory Board following FDA 510(k) clearance of its VAOT software. VAOT is an AI-based triage tool designed to assist radiologists in identifying peripheral arterial disease and vascular occlusion in the lower extremities to enable earlier diagnosis and intervention.

The global microcatheter market is valued at USD 1.05 billion in 2025 and is projected to reach USD 1.79 billion by 2035, expanding at a CAGR of 5.53%. Growth is driven by increasing adoption of minimally invasive cardiovascular and neurovascular procedures, rising prevalence of cardiovascular and neurovascular disorders, and advancements in catheter technologies. Aspiration microcatheters lead with 36% market share, while steerable microcatheters are the fastest-growing segment. North America dominates with 34% of global revenues, with Asia-Pacific emerging as the fastest-growing region.

Champlain Investment Partners completely exited its position in ServisFirst Bancshares, selling 1.57 million shares worth approximately $124.23 million. However, the exit appears to be part of broader fund downsizing rather than a targeted judgment on the company, as Champlain's reportable AUM contracted by roughly $2 billion quarter-over-quarter. The position represented only 1.14% of the fund's prior-quarter holdings.

Boston Scientific is well-positioned to capitalize on global aging demographics, with products addressing age-related conditions like atrial fibrillation, chronic pain, and Parkinson's disease. Recent acquisitions of Penumbra and Silk Road Medical expand its stroke treatment capabilities. Despite strong fundamentals and double-digit growth, the stock has been beaten down following conservative 2026 guidance, creating a potentially attractive valuation opportunity.

Investor rights law firm Halper Sadeh LLC is investigating four companies for potential federal securities law violations and breaches of fiduciary duties related to their merger or acquisition transactions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the proposed deals.

Monteverde & Associates PC, a class action law firm, is investigating four merger transactions: Penumbra's sale to Boston Scientific, RAPT Therapeutics' sale to GSK, Nathan's Famous' sale to Smithfield Foods, and Lisata Therapeutics' sale to Smithfield Foods. The firm is seeking shareholders who may have concerns about these deals.

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties related to their merger or acquisition transactions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the proposed deals.

Boston Scientific has issued a recall of certain AXIOS stents and electrocautery-enhanced delivery systems due to deployment and expansion difficulties. As of December 23, the company reported 167 serious injuries and 3 deaths associated with the issue. The FDA is actively reviewing the potentially high-risk device issue. The complications occur during delivery, not after implantation.

Investor rights law firm Halper Sadeh LLC is investigating three companies for potential securities law violations and fiduciary duty breaches related to major transactions: Penumbra's $374 per share sale to Boston Scientific, Calavo's acquisition by Mission Produce for $14.85 cash plus stock, and Mission Produce's merger with Calavo. The firm is seeking increased consideration for shareholders and additional disclosures.

This week's M&A activity spans major acquisitions and bankruptcies. Boston Scientific agreed to acquire Penumbra for $14.6 billion, expanding its neurovascular presence. Devon Energy and Coterra Energy are in merger discussions to create a major shale producer. Paramount Skydance's lawsuit against Warner Bros. Discovery was rejected by a Delaware judge. BitMine Immersion invested $200 million in MrBeast's Beast Industries. Meanwhile, spirits producers Stoli Group USA and Kentucky Owl converted their Chapter 11 bankruptcies to Chapter 7 liquidation, and Sailormen Inc., a Popeyes franchisee, filed for bankruptcy.

The global neurovascular devices market is projected to grow from USD 3.6 billion in 2024 to USD 6.8 billion by 2032, driven by increasing prevalence of neurovascular disorders, technological advancements, and growing preference for minimally invasive procedures. North America leads the market with 30% share, while Asia-Pacific emerges as a major growth driver. Key players include Johnson & Johnson, Medtronic, Stryker, and Terumo Corporation.